07:00 , Mar 16, 2015 |  BioCentury  |  Finance

Chiasma's private decision

Chiasma Inc. profiles as a potential IPO candidate with a late-stage asset on the verge of registration. But MPM Capital's Todd Foley told BioCentury that the recent unexpected return of commercial rights for its octreotide...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Financial News

Chiasma completes venture financing

Chiasma Inc. , Jerusalem, Israel   Business: Endocrine/Metabolic, Infectious, Drug delivery   Date completed: 2015-02-27   Type: Venture financing   Raised: $70 million   Investors: Rock Springs Capital; Sofinnova Ventures; MPM Capital; F2 Capital; 7...
02:37 , Feb 28, 2015 |  BC Extra  |  Financial News

Chiasma closes $70M series E round

Chiasma Inc. (Jerusalem, Israel) closed an oversubscribed $70 million series E round led by an undisclosed crossover fund. New investors Rock Springs Capital and Sofinnova Ventures participated, as did existing investors MPM Capital; F2 Capital;...
01:27 , Jul 24, 2012 |  BC Extra  |  Financial News

Chiasma raises $38.5M in series D

Chiasma Inc. (Jerusalem, Israel) raised $38.5 million in a series D round co-led by new investor Abingworth and existing investor MPM Capital. Existing investors 7 Med Health Ventures; Arch Venture Partners; F3 Ventures; and Chiasma...